Thanks for reaching out, Peter.

Teva is committed to responsibly pricing our medicines to reflect their value to patients, payers and society. There have been no WAC price increases on COPAXONE in the last three years. Further, for the last three years, the average WAC increase has been at or below three percent each year across all Teva products. We continuously evaluate our portfolio of products to look for opportunities to reduce costs for patients and the healthcare system and are dedicated to working with policymakers and stakeholders at both the federal and local levels on solutions that will address patient out-of-pocket costs.

As you may also know, Teva is also the leading generic company in the world and makes 10 percent of all medicines distributed in the US, introducing regular and significant savings and access to affordable medicine every day.